Kyowa Kirin
Kyowa Kirin Co., Ltd., a prominent biopharmaceutical company, is headquartered in Tokyo, Japan (JP). Founded in 1949, the company has established a strong presence in the global healthcare industry, focusing on innovative drug development in areas such as oncology, nephrology, and immunology. Kyowa Kirin is renowned for its unique biologics and small molecule therapies, which leverage advanced technologies to address unmet medical needs. The company has achieved significant milestones, including the successful launch of several key products that have positioned it as a leader in the biopharmaceutical sector. With a commitment to research and development, Kyowa Kirin continues to expand its operational footprint across major regions, including North America, Europe, and Asia, solidifying its market position through strategic partnerships and a robust pipeline of therapeutic solutions.
DitchCarbon Score
How does Kyowa Kirin's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kyowa Kirin's score of 72 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Kyowa Kirin's reported carbon emissions
In 2023, Kyowa Kirin reported total carbon emissions of approximately 82,102,000 kg CO2e globally, with emissions distributed across Scope 1 (23,507,000 kg CO2e), Scope 2 (23,507,000 kg CO2e), and Scope 3 (81,020,000 kg CO2e). In Japan, the company recorded Scope 1 emissions of about 16,362,000 kg CO2e and Scope 2 emissions of approximately 3,974,000 kg CO2e, leading to a total of 20,336,000 kg CO2e for Scope 1 and 2 combined. Kyowa Kirin has set ambitious reduction targets, aiming for a 55% reduction in Scope 1 and Scope 2 emissions by 2030 compared to 2019 levels. Additionally, the company targets a 30% reduction in Scope 3 emissions by the same year. These commitments align with their medium-term goals, which include an interim target of a 51% reduction in emissions by 2024. The company is also committed to achieving net-zero greenhouse gas emissions across its entire value chain by 2050, as part of the Kirin Group Environmental Vision 2050. This comprehensive approach underscores Kyowa Kirin's dedication to sustainability and climate action within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 17,244,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 34,687,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Kyowa Kirin is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
